Early diagnosis, clinical management, and follow-up of cardiovascular events with ponatinib

Casavecchia G.;Galderisi M.;Novo G.;Gravina M.;Santoro C.;Agricola E.;Capalbo S.;Zicchino S.;Cameli M.;De Gennaro L.;Righini F. M.;Monte I.;Tocchetti C. G.;Brunetti N. D.;Cadeddu C.

Penultimo

;Mercuro G.

Ultimo

2020-01-01

---

Abstract

Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by neoplastic transformation of pluripotent cells due to a typical cytogenetic and molecular mutation known as Philadelphia (Ph) chromosome. In 2001, the introduction of the tyrosine kinasis inhibitor (TKI) imatinib as a therapeutic strategy for CML with PH chromosome mutation represented an important step towards treatment of these patients, and nowadays, this drug represents the gold therapeutic standard in this clinical setting. A second generation of TKIs (dasatinib, nilotinib, and bosutinib) showed an effective action in all patients with mutations resistant to imatinib. Ponatinib is a third-generation TKI and is the only inhibitor with activity against T3151 mutation. The impact of ponatinib on cardiovascular events was first evaluated in the PACE trial. We therefore report and discuss most relevant evidence currently available on cardiovascular events associated with the use of ponatinib. Though many exams can be used for diagnosis and follow-up of this kind of cardiotoxicity, echocardiography seems to have a pivotal role thanks to its feasibility, availability, and low cost.